search

Active clinical trials for "Glomerulonephritis, IGA"

Results 91-100 of 154

Pilot Study of Velcade® in IgA Nephropathy

Chronic Kidney DiseaseIgA Nephropathy

The primary objective of this study is to investigate the ability of Velcade® (bortezomib) to induce complete or partial remission in patients with severe IgA nephropathy. The secondary objectives are to assess clinical outcomes relating to safety and efficacy, such as infection, malignancy, preservation of renal function, partial responders, relapse rate, and to study mechanistic assays to predict remission.

Completed12 enrollment criteria

A Controlled Study of Uric Acid on the Progression of IgA Nephropathy

IgA Nephropathy

This prospective, randomized controlled study will evaluate the effect of uric acid on the progression of IgA nephropathy.

Completed14 enrollment criteria

Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy

IGA Nephropathy

Immunoglobulin A (IgA) nephropathy is the most common type of primary glomerulonephritis in the world. A wealth of literature suggests that vitamin D and its analogs have profound effects on immune system function and glomerular mesangial cell proliferation. Calcitriol, an active form of vitamin D, is commonly used for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney diseases. Therefore, the investigators plan to conduct a open-label single-arm study to evaluate the safety and efficacy of calcitriol in the treatment of IgA nephropathy. Ten patients with biopsy-proven IgA nephropathy and persistent proteinuria despite conventional therapy will be recruited. They will be treated with calcitriol for 12 weeks. Proteinuria, renal function, serum and urinary inflammatory markers will be monitored. This study will explore the potential anti-proteinuric and anti-inflammatory effects of calcitriol in the treatment of IgA nephropathy, which is a major cause of dialysis-dependent renal failure.

Completed19 enrollment criteria

Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized...

Biopsy-confirmed IgA NephropathyProteinuria Less Than 0.5 g Per Day2 more

Immunoglobulin A (IgA) nephropathy is the most common type of primary glomerulonephritis in the world. The treatment of IgA nephropathy with normal renal function and minimal proteinuria is unknown. Since angiotensin-converting enzyme (ACE) inhibitors reduce proteinuria and retard the rate of decline of renal function in chronic proteinuric nephropathies, including IgA nephropathy. The investigators conduct a randomized control study to evaluate the efficacy of ACE inhibitor in the treatment of early IgA nephropathy. Sixty patients with biopsy-proven IgA nephropathy and minimal proteinuria are recruited. They will be randomized to ramipril for 5 years or no treatment. Blood pressure, proteinuria and renal function will be monitored. This study will explore the effects of ACE inhibitor in the treatment of early IgA nephropathy, which is a major cause of dialysis-dependent renal failure.

Completed13 enrollment criteria

An Multi-site Prospective Study to Assess the Efficacy and Safety of MMF in the Treatment of Proliferative...

IgA Nephropathy (IgAN)

In order to treat proliferative IgA Nephropathy(IgAN), The investigators designed an open, prospective, randomized parallel study to access the efficacy and safety of MMF compared to corticosteroid . Patients who fulfill the inclusion criteria will be randomized in a 1:1 ratio to either the MMF group or corticosteroid group.

Completed13 enrollment criteria

BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration...

IgA Nephropathy

The purpose of this study is to evaluate the efficacy and safety of subcutaneous blisibimod administration in addition to standard therapy in patients with biopsy proven IgA Nephropathy with persistent proteinuria of between 1-6 g/day.

Completed15 enrollment criteria

The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy...

IgA Nephropathy

This is a single center,prospective,no-controlled clinical trial

Completed9 enrollment criteria

Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis

IGA Glomerulonephritis

This study evaluates prospectively the effects of an anti-angiotensin II regimen on renal outcome in patients with mesangioproliferative glomerulonephritis followed-up for 10 years.

Completed7 enrollment criteria

Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study

IGA Nephropathy

The study will investigate the effect of PL-56 on albumin leakage and renal function (glomerular filtration rate) in patients with IgA nephropathy. It will also assess the safety of treatment with PL-56.

Completed24 enrollment criteria

Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade

IgA Nephropathy

Study objective: To investigate the potential anti-proteinuric efficacy of aliskiren, a novel direct renin inhibitor (DRI), in addition to angiotensin receptor blocker (ARB) in immunoglobulin A nephropathy (IgAN) patients at risk of developing progressive renal failure.

Completed20 enrollment criteria
1...91011...16

Need Help? Contact our team!


We'll reach out to this number within 24 hrs